Martin G. Baum – President, Chairman and Chief Executive Officer
Martin Baum has been involved in the pharmaceutical and biotechnology industries for more than 20 years. He began his career with Merrell Dow Pharmaceuticals and subsequently moved through the ranks at GlaxoSmithKline Pharmaceuticals. He later transitioned his career to Skye Pharma, PLC. Mr. Baum was instrumental in starting three brand pharmaceutical companies including, Brightstone Pharma, DJ Pharma, and TEAMM Pharmaceuticals, Inc. At DJ Pharma, Mr. Baum held the position of Senior Vice President, Commercial Operations from December 1998 until July 2000. Under Mr. Baum’s direction, the company achieved net revenue in excess of $60 million and profitability within two years. The company was sold to Biovail Corporation in October 2000, for $212 million. Based on his success at DJ Pharma, Mr. Baum founded TEAMM. At TEAMM, he was President and Chief Executive Officer. He later orchestrated the company’s sale to Accentia Biopharma. While at Accentia, Mr. Baum served as company COO and directed the initiative to take Accentia public. Mr. Baum has extensive industry experience from conceptual product design to product commercialization. In addition, he has developed strong business relationships within the financial markets, having raised over $250M during his tenure, while developing these companies. He has worked closely in all stages of FDA product approvals, medical device approvals, drug delivery technology development and generic product market entries. He has successfully led companies to continued growth, through numerous business cycles. Mr. Baum is a graduate of The University of Toledo, with B.S. degrees in Human Life Sciences and Business Administration.
Steve Lutz – Chief Operating Officer
Steve has had an exceptional career in all aspects of pharma business and commercialization. A founder of Praelia Pharmaceuticals, Steve was able to direct and develop a new health care entity into both the consumer and prescription pharmaceutical arenas. With Cornerstone Therapeutics, Mr. Lutz was Executive Vice President of Operations as well as a founding stockholder. He was President of Aristos, Cornerstone’s generics division and achieved $40m of net profit in its first two years of operations. Steve has held various executive positions in the industry including Director, Trade Sales for Verum and acted as National Account Manager for both Biovail and Shire. Steve holds a B.A. in Political Science and Sociology from Moravian College in Bethlehem, Pennsylvania.
Chenyqua Baldwin – Chief Financial Officer
As Chief Financial Officer, Chenyqua has full responsibility for all financial controls and reporting within Vestiq and is intimately familiar with EDI and the intricacies of accounting for drug distribution through multiple channels and through separated independent entities. She also held the same position at Praelia Pharmaceuticals. Chenyqua was Chief Accounting Officer, Controller and VP Finance for Cornerstone Therapeutics, Inc., as well as Director of Finance for Biovail. Chenyqua is a fully accredited CPA with a Masters of Accounting degree and a Bachelor of Science, Business Administration Degree, both from the University of North Carolina.
Wade A. Harper – Executive Vice President of Commercial Operations
Wade Harper is a co-founder of Praelia Pharmaceuticals where he also served as Executive Vice President, Sales. Prior to his work at Praelia, Mr. Harper served as National Sales Director for both the office-based and hospital-based sales forces at Cornerstone Therapeutics, Inc. While at Cornerstone, Mr. Harper also managed Sales Operations and Sales Analytics and acted as Regional Sales Manager. Mr. Harper held several additional roles throughout his 15 years in the pharmaceutical industry including sales, training and management positions with both Dura and Elan Pharmaceuticals.
Randall J. Acosta – Executive Vice President of Trade and National Accounts
Randy Acosta has over 25 years experience in both the brand and generic pharmaceutical industry with particular expertise in product commercialization, sales and distribution within trade and managed market segments. He has developed and managed several successful national account divisions for established and emerging pharmaceutical companies including Endo, Apotex, Sandoz and Allergan. Additionally, his expertise includes Regulatory, Quality Systems, cGMP, ISO 9000, 9001 and 13485, patent litigation, product development and FDA pathways. Randy is a graduate of California State University of Fullerton and holds a B.A. in Biological Science.